Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 71pembrolizumab 70Pemetrexed 62Cisplatin 46Nivolumab 28Paclitaxel 27durvalumab 26Specimen Handling 25osimertinib 23Docetaxel 23Magnetic Resonance Spectroscopy 21Gemcitabine 17Cetuximab 15130-nm albumin-bound paclitaxel 15atezolizumab 14amivantamab 14Radiotherapy 12Radiosurgery 12lazertinib 11Ipilimumab 9Bevacizumab 9cemiplimab 8Taxes 8Drug Therapy 8alectinib 7Ramucirumab 7Observation 7Radiation 6Leucovorin 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × 18-O-demethylcervinomycin A2 × 30 days × Clear all
NCT05351788 2026-05-12

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
110 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡